(Q37961390)

English

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 August 2017

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study (English)

1 reference

Europe PubMed Central

26 August 2017

0 references

carcinoid syndrome

1 reference

based on heuristic

inferred from title

object named as

Marc Peeters

4

0 references

John D Hainsworth

2

object named as

John D Hainsworth

1 reference

Europe PubMed Central

26 August 2017

author name string

Marianne E Pavel

1

1 reference

Europe PubMed Central

26 August 2017

Eric Baudin

3

1 reference

Europe PubMed Central

26 August 2017

Dieter Hörsch

5

1 reference

Europe PubMed Central

26 August 2017

Robert E Winkler

6

1 reference

Europe PubMed Central

26 August 2017

Judith Klimovsky

7

1 reference

Europe PubMed Central

26 August 2017

David Lebwohl

8

1 reference

Europe PubMed Central

26 August 2017

Valentine Jehl

9

1 reference

Europe PubMed Central

26 August 2017

Edward M Wolin

10

1 reference

Europe PubMed Central

26 August 2017

Kjell Öberg

11

1 reference

Europe PubMed Central

26 August 2017

Eric Van Cutsem

12

1 reference

Europe PubMed Central

26 August 2017

James C Yao

13

1 reference

Europe PubMed Central

26 August 2017

RADIANT-2 Study Group

14

1 reference

Europe PubMed Central

26 August 2017

language of work or name

0 references

publication date

25 November 2011

1 reference

Europe PubMed Central

26 August 2017

1 reference

Europe PubMed Central

26 August 2017

378

1 reference

Europe PubMed Central

26 August 2017

2005-2012

1 reference

Europe PubMed Central

26 August 2017

9808

1 reference

Europe PubMed Central

26 August 2017

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting the mTOR signaling network for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Current development of mTOR inhibitors as anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The TOR pathway: a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Neuroendocrine neoplasms of the lung: a prognostic spectrum.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Issues in using progression-free survival when evaluating oncology products

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961742-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(11)61742-X

1 reference

Europe PubMed Central

26 August 2017

1 reference

Europe PubMed Central

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37961390&oldid=2088665454"